FDA Extends Nexplanon Use
US study data showed zero pregnancies in years 4 and 5 of etonogestrel implant use.
By
Kathryn Wighton
January 20, 2026
Clinical Scorecard: FDA Extends Nexplanon Use
At a Glance
Category Detail
Condition Pregnancy prevention Key Mechanisms Etonogestrel implant providing long-acting contraception Target Population Women of reproductive potential, ages 18-35, with varying BMI Care Setting Certified healthcare providers and pharmacies
Key Highlights
Nexplanon use extended from 3 years to 5 years for pregnancy prevention Zero pregnancies reported during years 4 and 5 of use No new safety findings during extended use Changes in menstrual bleeding patterns are common adverse reactions REMS program implemented to mitigate insertion and removal complications Guideline-Based Recommendations
Diagnosis
Assess reproductive potential and suitability for long-acting contraception Management
Provide Nexplanon as a contraceptive option for up to 5 years Monitoring & Follow-up
Monitor for changes in menstrual bleeding patterns and other adverse reactions Risks
Potential complications from improper insertion and removal Patient & Prescribing Data
Women aged 18-35, including those with a BMI range from 17.2 to 64.3 kg/m2
Effective contraception with no pregnancies reported during extended use
Clinical Best Practices
Ensure proper training for healthcare providers on insertion and removal Implement REMS to enhance patient safety Educate patients on potential menstrual changes and adverse reactions References
